180 related articles for article (PubMed ID: 10404437)
1. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?
Hurst R; White DE; Heiss J; Lee DS; Rosenberg SA; Schwartzentruber DJ
J Immunother; 1999 Jul; 22(4):356-62. PubMed ID: 10404437
[TBL] [Abstract][Full Text] [Related]
2. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
3. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
Spanknebel K; Cheung KY; Stoutenburg J; Hurst-Wicker K; Hesdorffer C; Deraffele G; Kaufman HL
Ann Surg Oncol; 2005 May; 12(5):381-90. PubMed ID: 15915372
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
5. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
6. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
7. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
Sherry RM; Pass HI; Rosenberg SA; Yang JC
Cancer; 1992 Apr; 69(7):1850-5. PubMed ID: 1551067
[TBL] [Abstract][Full Text] [Related]
8. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
Sheehan JP; Sun MH; Kondziolka D; Flickinger J; Lunsford LD
J Neurosurg; 2003 Feb; 98(2):342-9. PubMed ID: 12593621
[TBL] [Abstract][Full Text] [Related]
9. Clinical study of brain metastasis of renal cell carcinoma.
Harada Y; Nonomura N; Kondo M; Nishimura K; Takahara S; Miki T; Okuyama A
Eur Urol; 1999 Sep; 36(3):230-5. PubMed ID: 10450008
[TBL] [Abstract][Full Text] [Related]
10. Surgical resection of brain metastases from renal cell carcinoma in 50 patients.
Wroński M; Arbit E; Russo P; Galicich JH
Urology; 1996 Feb; 47(2):187-93. PubMed ID: 8607231
[TBL] [Abstract][Full Text] [Related]
11. Survival of brain metastatic patients in Yazd, Iran.
Akhavan A; Binesh F; Heidari S
Asian Pac J Cancer Prev; 2014; 15(8):3571-4. PubMed ID: 24870759
[TBL] [Abstract][Full Text] [Related]
12. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Lindsey KR; Rosenberg SA; Sherry RM
J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
[TBL] [Abstract][Full Text] [Related]
13. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
14. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma.
Hara W; Tran P; Li G; Su Z; Puataweepong P; Adler JR; Soltys SG; Chang SD; Gibbs IC
Neurosurgery; 2009 Feb; 64(2 Suppl):A26-32. PubMed ID: 19165071
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
[TBL] [Abstract][Full Text] [Related]
16. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
17. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Rosenberg SA; Yang JC; White DE; Steinberg SM
Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
[TBL] [Abstract][Full Text] [Related]
18. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.
Karp SE
J Immunother; 1998 Jan; 21(1):56-61. PubMed ID: 9456437
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment of 70 patients with brain metastases from breast carcinoma.
Wroński M; Arbit E; McCormick B
Cancer; 1997 Nov; 80(9):1746-54. PubMed ID: 9351543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]